Obstetrics & Gynecology, Gynecologic Oncology · Columbia, SC
NPI
1528040854
Since 2005
Specialty
Obstetrics & Gynecology, Gynecologic Oncology
Code 207VX0201X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
166 Stoneridge Dr
Columbia, SC, 29210
Phone (803) 461-3000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
130,679 services
Medicare patients, 2024
522
Average age 74
Drug cost, 2024
$875K
714 prescriptions
Company payments, 2025
$1,499
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James A Williams was code J9267 (injection, paclitaxel, 1 mg), 39,272 times for 42 patients. In total James A Williams billed 130,679 services in 139 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-09-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9267 Injection, paclitaxel, 1 mg | Office | 39,272 | 42 | $0.08 | $3,202 |
| J0185 Injection, aprepitant, 1 mg | Office | 18,590 | 46 | $1.34 | $25K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 11,875 | 98 | $0.09 | $1,104 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 11,800 | 40 | $4.40 | $52K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 8,000 | 12 | $40.71 | $326K |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 3,620 | 13 | $45.99 | $166K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,036 | 13 | $20.55 | $62K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,575 | 64 | $0.09 | $233 |
| A9585 Injection, gadobutrol, 0.1 ml | Office | 1,650 | 20 | $0.25 | $416 |
| 36415 Venipuncture Blood Collection | Office | 1,173 | 213 | $8.52 | $9,997 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,108 | 15 | $0.22 | $247 |
| 85025 Blood Count | Office | 1,093 | 172 | $7.59 | $8,295 |
| J9045 Injection, carboplatin, 50 mg | Office | 1,085 | 42 | $2.84 | $3,079 |
| 80048 Clinical Chemistry | Office | 1,074 | 181 | $8.28 | $8,891 |
| 80076 Clinical Chemistry | Office | 771 | 159 | $8.01 | $6,176 |
By year: 2022 $1.2M for 97,627 services; 2023 $1.2M for 126,614 services; 2024 $1.8M for 130,679 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,173 | 213 | $8.52 | $9,997 |
| 85025 Blood Count | 1,093 | 172 | $7.59 | $8,295 |
| 80048 Clinical Chemistry | 1,074 | 181 | $8.28 | $8,891 |
| 80076 Clinical Chemistry | 771 | 159 | $8.01 | $6,176 |
| 86304 Immunoassay | 622 | 160 | $20.00 | $12K |
| 84443 Clinical Chemistry | 37 | 12 | $16.27 | $602 |
| 83550 Clinical Chemistry | 24 | 20 | $8.57 | $206 |
| 83540 Clinical Chemistry | 24 | 20 | $6.34 | $152 |
| 82728 Clinical Chemistry | 23 | 18 | $13.36 | $307 |
| 85044 Blood Count | 23 | 18 | $4.22 | $97.06 |
Medicare prescription drug claims, 2024
In 2024, the drug James A Williams prescribed most often to Medicare patients was Letrozole, with 87 prescriptions and refills. In total James A Williams wrote 714 Medicare prescriptions that cost $875K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 87 | 154 | 21 | $2,101 |
| Megestrol Acetate Generic | 58 | 78 | 14 | $4,524 |
| Dexamethasone Generic | 52 | 52 | 37 | $500 |
| Ondansetron Odt Ondansetron | 49 | 49 | 44 | $603 |
| Eliquis Apixaban | 42 | 59 | Under 11 | $34K |
| Promethazine Hcl Generic | 33 | 33 | 23 | $212 |
| Dicyclomine Hcl Generic | 28 | 28 | 27 | $21.77 |
| Prochlorperazine Maleate Generic | 25 | 25 | 20 | $197 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 24 | 24 | 24 | $106 |
| Rubraca Rucaparib Camsylate | 20 | 20 | Under 11 | $208K |
| Exemestane Generic | 18 | 18 | Under 11 | $2,332 |
| Ondansetron Hcl Generic | 17 | 17 | 13 | $62.68 |
| Gabapentin Generic | 14 | 18 | Under 11 | $140 |
| Potassium Chloride Generic | 13 | 17 | 11 | $435 |
| Lenvima Lenvatinib Mesylate | 12 | 12 | Under 11 | $253K |
Brand drugs: 110 claims; generic drugs: 604 claims; opioid claims: 61.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James A Williams $1,499 ($1,499 in general payments such as food, travel and fees) from 31 companies. The largest payer was Novartis Pharmaceuticals Corporation with $166.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 7 | $166 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $119 |
| Lilly USA, LLC LLY | 4 | $107 |
| Genentech USA, Inc. ROG.SW | 4 | $101 |
| Merck Sharp & Dohme LLC MRK | 3 | $87.39 |
| Immunocore Limited IMCR | 3 | $70.84 |
| Incyte Corporation INCY | 3 | $63.11 |
| Abbvie Inc. ABBV | 2 | $60.02 |
| Pfizer Inc. PFE | 3 | $58.71 |
| Daiichi Sankyo Inc. 4568.T | 2 | $53.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.